Contagious molluscum in swimmers with atopic dermatitis: transmission risk, clinical challenges and impact on sports participation - a narrative review
DOI:
https://doi.org/10.12775/JEHS.2026.88.68004Keywords
molluscum contagiosum, atopic dermatitis, swimmers, transmission risk, infection control, sports participation, return-to-playAbstract
Background. Molluscum contagiosum (MC) is a common cutaneous poxvirus infection transmitted primarily through direct skin-to-skin contact and autoinoculation, with indirect spread via fomites considered plausible in shared environments. Swimmers may face heightened exposure to communal facilities and equipment, while atopic dermatitis (AD) can amplify susceptibility and disease burden through skin-barrier dysfunction and itch-driven dissemination. These factors can create clinical uncertainty about transmission risk, complicate management, and contribute to unnecessary restriction from training and competition.
Material and methods. A narrative review was conducted using targeted searches of PubMed/MEDLINE and Google Scholar, supplemented by screening of reference lists and verification through official journal/publisher records. Search terms combined MC with AD-related constructs (eczema, filaggrin/barrier dysfunction) and aquatic/sport contexts (swimming, pools, athletes, transmission, fomites, return-to-play), and were expanded to include contemporary therapeutics relevant to clearance timelines.
Results. The evidence base supports contact and autoinoculation as the dominant transmission pathways for MC, while direct evidence for chlorinated pool water as a primary vehicle remains limited; the swimmer setting is more plausibly “facility-associated” through shared surfaces, changing areas, and personal items. AD consistently emerges as a risk amplifier and phenotype modifier, with barrier dysfunction and pruritus promoting wider lesion dissemination and eczematization that can obscure diagnosis and complicate treatment tolerability. Therapeutic advances supported by randomized trials, including provider-applied cantharidin 0.7% formulations and topical nitric oxide–releasing berdazimer gel, offer practical options to reduce lesion burden and support time-sensitive participation planning.
References
Meza-Romero R, Navarrete-Dechent C, Downey C, et al. Molluscum contagiosum: an update and review of new perspectives in etiology, diagnosis, and treatment. Clin Cosmet Investig Dermatol. 2019 May 30:12:373-381. https://doi.org/10.2147/ccid.s187224
Forbat E, Al-Niaimi F, Ali FR. Molluscum Contagiosum: Review and Update on Management. Pediatr Dermatol. 2017 Sep;34(5):504-515. https://doi.org/10.1111/pde.13228
Robinson G, Townsend S, Jahnke MN. Molluscum Contagiosum: Review and Update on Clinical Presentation, Diagnosis, Risk, Prevention, and Treatment. Curr Dermatol Rep. 2020. https://doi.org/10.1007/s13671-020-00289-z
Manti S, Amorini M, Cuppari C, et al. Filaggrin mutations and Molluscum contagiosum skin infection in patients with atopic dermatitis. Ann Allergy Asthma Immunol. 2017 Nov;119(5):446-451. https://doi.org/10.1016/j.anai.2017.07.019
Kojima R, et al. Association between filaggrin gene mutations and the clinical features of molluscum contagiosum: The Yamanashi Adjunct Study of the Japan Environment and Children's Study. J Dermatol. 2024 Apr;51(4):484-490. https://doi.org/10.1111/1346-8138.17157
Hill RC, Parikh AK, et al. Molluscum contagiosum is associated with atopic dermatitis and sexually transmitted infections in a matched case-control study using a national database. Int J STD AIDS. 2024 Nov;35(13):1050-1054. https://doi.org/10.1177/09564624241276571
Silverberg NB. Molluscum contagiosum virus infection can trigger atopic dermatitis disease onset or flare. Cutis. 2018 Sep;102(3):191-194. PMID:30372710.
Montyn Lücher NEG, Okoh UJ, Silverberg NB. Systematic Review of the Epidemiology and Risk Factors for Nonsexual Transmission of Warts and Molluscum in Children. Pediatr Dermatol. 2025 Sep-Oct;42(5):927-932. https://doi.org/10.1111/pde.16002
Sfyri E, Kefala V, et al. Viral Cutaneous Infections in Swimmers: A Preliminary Study. Water (Basel). 2021. 13(23), 3401. https://doi.org/10.3390/w13233401
Pujalte GGA, et al. More Than Skin Deep: Dermatologic Conditions in Athletes. Sports Health. 2023 Jan-Feb;15(1):74-85. https://doi.org/10.1177/19417381211065026
Anderson BJ, Wilz L, Peterson A. The Identification and Treatment of Common Skin Infections. J Athl Train. 2023 Jun 1;58(6):502-510. https://doi.org/10.4085/1062-6050-0142.22
Nowicka D, Bagłaj-Oleszczuk M, Maj J. Infectious diseases of the skin in contact sports. Adv Clin Exp Med. 2020 Dec;29(12):1491-1495. https://doi.org/10.17219/acem/129022
Truong A, Miller A, Asch S. Pediatric Sports Dermatology. Pediatr Rev. 2024 May 1;45(5):271-284. https://doi.org/10.1542/pir.2023-006040
Eichenfield LF, McFalda W, Brabec B, et al. Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials. JAMA Dermatol. 2020 Dec; 156(12):1315-1323. https://doi.org/10.1001/jamadermatol.2020.3238
Eichenfield LF, Kwong P, et al. Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum. Am J Clin Dermatol. 2021 Mar;22(2):257-265. https://doi.org/10.1007/s40257-020-00570-8
Browning JC, Enloe C, Cartwright M, et al. Efficacy and Safety of Topical Nitric Oxide−Releasing Berdazimer Gel in Patients With Molluscum Contagiosum: a Phase 3 randomized clinical trial. JAMA Dermatol. 2022 Aug 1;158(8):871-878. https://doi.org/10.1001/jamadermatol.2022.2721
Sugarman JL, Hebert A, Browning JC, et al. Berdazimer gel for molluscum contagiosum: An integrated analysis of 3 randomized controlled trials. 2024 Feb;90(2):299-308. https://doi.org/10.1016/j.jaad.2023.09.066
Paller AS, et al. Berdazimer gel for molluscum contagiosum in patients with atopic dermatitis. Pediatr Dermatol. 2024 May-Jun;41(3):438-444. https://doi.org/10.1111/pde.15575
Keam SJ. Cantharidin topical solution 0.7%: First Approval (YCANTH). Paediatr Drugs. 2024 Jan;26(1):95-100. https://doi.org/10.1007/s40272-023-00600-y
Keam SJ. Berdazimer topical gel 10.3%: First Approval. Drugs. 2024 Mar;84(3):363-368. https://doi.org/10.1007/s40265-024-02012-9
FDA. FDA approves first treatment for molluscum contagiosum. 24 Jul 2023.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Oksana Zinko, Aleksandra Zimnoch-Włodarczyk, Maciej Łapiński, Michał Napierała, Kinga Ciecierska, Krystyna Wasilkowska, Sylwia Łatkowska, Laura Więcek, Kinga Ściurka

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 3
Number of citations: 0